A polyphenol-based coating used on bacterial strains to protect them from oxygen’s harmful effects could pave the development of “living biotherapeutics” that are more resistant to the manufacturing process.
4D pharma’s Live Biotherapeutic Product (LBP), appears to enhance anti-tumour activity and increase the efficacy of an immunotherapy used to treat certain tumours, says a German research team.
‘Designer’ biotherapeutics rationally designed to address the dysbiotic microbiome seen in Crohn’s disease and ulcerative colitis may be the ‘breakthrough’ researchers are looking for in tackling these conditions.
French oncology firm, MaaT Pharma announces its intention to resume collection of donor stools as part of its microbiome-based research into tackling blood cancers, such as Acute Myeloid Leukaemia (AML).
New recommendations that address the safety of biological products containing live microorganisms, may help firms obtain a marketing authorisation that is so far proving elusive, according to a research team